Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets: 2022-2024

Historic Current Assets for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $142.1 million.

  • Taysha Gene Therapies' Current Assets rose 85.66% to $300.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.0 million, marking a year-over-year increase of 85.66%. This contributed to the annual value of $142.1 million for FY2024, which is 5.16% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Current Assets is $142.1 million, which was down 5.16% from $149.9 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Current Assets registered a high of $149.9 million during FY2023, and its lowest value of $96.4 million during FY2022.
  • Its 3-year average for Current Assets is $129.5 million, with a median of $142.1 million in 2024.
  • As far as peak fluctuations go, Taysha Gene Therapies' Current Assets soared by 55.44% in 2023, and later fell by 5.16% in 2024.
  • Taysha Gene Therapies' Current Assets (Yearly) stood at $96.4 million in 2022, then soared by 55.44% to $149.9 million in 2023, then dropped by 5.16% to $142.1 million in 2024.